<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管出版物</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;ff=20231108011057&amp;v=2.17.9.post6+86293ac&amp;utm _med ium=rss&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC- &amp;utm_source=Chrome<description>心血管亮点：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;ff=20231108011057&amp;v=2.17.9.post6+86293ac&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 11 月 8 日星期三 06:10:59 +0000</lastbuilddate><pubDate> Tue, 07 Nov 2023 06:00:00 -0500</pubDate><ttl> 120</ttl><item><title>心血管疾病孟德尔随机化：原理与应用</title><link/>https://pubmed.ncbi.nlm.nih.gov/37935836/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231108011057&amp;v=2.17.9.post6+86293ac<description>过去十年进行的大规模全基因组关联研究发现了许多与心脏代谢特征和风险因素相关的遗传变异。这些发现使孟德尔随机化 (MR) 设计成为可能，该设计使用遗传变异作为自然实验来改善因果推论来自观察数据。通过与随机对照试验中治疗的随机分配进行类比，当 DNA 是时，遗传等位基因的随机分离...... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 11 月 3 日：ehad736。doi：10.1093/eurheartj/ehad736。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">过去十年进行的大规模全基因组关联研究发现了许多与心脏代谢特征和风险因素相关的遗传变异。这些发现使孟德尔随机化 (MR) 设计成为可能，该设计使用遗传变异作为自然实验来改善因果推论来自观察数据。通过与随机对照试验中治疗的随机分配进行类比，当 DNA 在配子形成时从父母传递给后代时，遗传等位基因的随机分离预计会减少遗传关联中的混杂。孟德尔随机化分析提出了一组必须成立才能获得有效结果的假设。如果用作工具变量的遗传变异的假设得到充分证明，MR 研究可以告知假定的风险因素是否可能对疾病产生因果影响。孟德尔随机化近年来越来越多地应用于预测针对心血管危险因素的现有药物和新药物的疗效和安全性，并探索现有药物的再利用潜力。这篇综述文章介绍了 MR 设计的原理以及在心血管流行病学中的一些应用。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37935836/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231108011057&v=2.17.9.post6+86293ac">37935836</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad736>10.1093/eurheartj/ehad736</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37935836</guid><pubDate> Tue, 07 Nov 2023 06:00:00 -0500</pubDate><dc:creator>苏珊娜·C·拉尔森</dc:creator><dc:creator>亚当·巴特沃斯</dc:creator><dc:creator>史蒂芬·伯吉斯</dc:creator><dc:date>2023-11-07</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>心血管疾病孟德尔随机化：原理与应用</dc:title><dc:identifier>下午:37935836</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad736</dc:identifier></item><item><title>非心脏手术前停止与继续肾素-血管紧张素系统抑制：SPACE 试验</title><link/>https://pubmed.ncbi.nlm.nih.gov/37935833/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231108011057&amp;v=2.17.9.post6+86293ac<description>结论：在非心脏手术前停用 RAS 抑制剂并不能减少心肌损伤，并且可能增加临床上显着的急性高血压的风险。这些发现需要在未来的研究中得到证实。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 11 月 7 日：ehad716。doi：10.1093/eurheartj/ehad716。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：血流动力学不稳定与围手术期心肌损伤有关，特别是在接受肾素血管紧张素系统（RAS）抑制剂（血管紧张素转换酶抑制剂/血管紧张素 II 受体阻滞剂）的患者中。是否停止使用 RAS 抑制剂以尽量减少低血压，或持续使用RAS抑制剂以避免高血压、减少围手术期心肌损伤仍不清楚。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：从 2017 年 7 月 31 日至 2021 年 10 月 1 日，年龄≥60 岁接受选择性非心脏手术的患者被随机分配到英国六个中心根据现有医疗状况停用或继续服用 RAS 抑制剂。根据其药代动力学特征，在手术前选择不同的持续时间（2-3 天）。对研究人员、鸡群和患者不公开的主要结果是心肌损伤 [血浆高敏肌钙蛋白-T (hs-TnT) ≥ 15 ng/术后 48 小时内升高，或术前 hs-TnT ≥15 ng/L 升高≥5 ng/L]。术后 48 小时内发生的预先指定的不良血流动力学事件包括急性高血压（>;180 mmHg）和低血压需要血管活性治疗。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：262 名参与者被随机分配继续使用 (n = 132) 或停止 (n = 130) RAS 抑制剂。随机停止使用 RAS 抑制剂的患者中有 58 名 (48.3%) 发生心肌损伤，而随机停止使用的患者中有 50 名 (41.3%) 发生心肌损伤。继续服用 RAS 抑制剂[比值比（继续）：0.77；95% 置信区间 (CI) 0.45-1.31]。与 7 相比，停用 RAS 抑制剂时高血压不良事件更频繁[16 (12.4%)]。 5.3%）继续使用 RAS 抑制剂[比值比（继续）：0.4；95% CI 0.16-1.00]。停止 RAS 抑制剂 [12 (9.3%)] 或继续使用 [11 (8.4%)] 时，低血压发生率相似。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：在非心脏手术前停用 RAS 抑制剂并不能减少心肌损伤，并且可能增加临床上显着的急性高血压的风险。这些发现需要在未来的研究中得到证实。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37935833/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231108011057&v=2.17.9.post6+86293ac">37935833</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad716>10.1093/eurheartj/ehad716</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37935833</guid><pubDate> Tue, 07 Nov 2023 06:00:00 -0500</pubDate><dc:creator>加雷斯·L·阿克兰</dc:creator><dc:creator>阿克谢库玛·帕特尔</dc:creator><dc:creator>汤姆·E·F·阿伯特</dc:creator><dc:creator>萨尔玛·贝古姆</dc:creator><dc:creator>普里扬西·迪亚斯</dc:creator><dc:creator>大卫·R·克兰</dc:creator><dc:creator>萨米尔·索马纳特</dc:creator><dc:creator>亚历山大·米德蒂奇</dc:creator><dc:creator>斯图尔特·克莱兰德</dc:creator><dc:creator>安娜·古铁雷斯·德尔·阿罗约</dc:creator><dc:creator>大卫·布瑞利</dc:creator><dc:creator>鲁珀特·M·皮尔斯</dc:creator><dc:creator>围手术期停止使用 ACE 抑制剂或血管紧张素 II 受体阻滞剂 (SPACE) 试验研究人员</dc:creator><dc:date>2023-11-07</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>非心脏手术前停止与继续肾素-血管紧张素系统抑制：SPACE 试验</dc:title><dc:identifier>下午:37935833</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad716</dc:identifier></item><item><title>心血管临床试验中的终点判定</title><link/>https://pubmed.ncbi.nlm.nih.gov/37935635/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231108011057&amp;v=2.17.9.post6+86293ac<description>终点裁定（EA）是当代心血管医学随机对照试验（RCT）的一个共同特征。终点裁定是指由一组专家评审员（称为临床终点委员会（CEC））进行的过程，验证按地点确定的潜在终点调查员。由 CEC 确定的满足预先指定的试验定义的事件随后用于分析。使用 EA 背后的基本原理是，它可能会减少潜在的... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 11 月 3 日：ehad718。doi：10.1093/eurheartj/ehad718。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">终点裁定（EA）是当代心血管医学随机对照试验（RCT）的一个共同特征。终点裁定是指由一组专家评审员（称为临床终点委员会（CEC））进行的过程，验证按地点确定的潜在终点然后，由 CEC 确定的满足预先指定的试验定义的事件用于分析。使用 EA 的基本原理是，它可以减少临床事件潜在的错误分类，从而减少统计噪声和偏差。但是，有人质疑这是否普遍正确，特别是考虑到 EA 显着增加了进行试验所需的时间、精力和资源。在此，我们比较了在主要心血管疾病中使用裁决与非裁决地点指定终点获得的总结估计两者均已报告的随机对照试验。根据这些数据，我们制定了一个框架，以确定哪些试验可能需要 EA，哪些试验可能是多余的。当心血管试验具有细致入微的主要终点、终点定义一致时，EA 的价值可能会更大实践不佳、数据完整性次优、操作者变异性较大以及缺乏盲法。如果主要终点是全因死亡或全因住院，则可能不需要 EA。相比之下，EA 可能适合更细致的终点例如心肌梗死、出血、门诊心力衰竭恶化、不稳定心绞痛或短暂性脑缺血发作。基于风险的裁决方法可能会在成本和准确性之间进行折衷。这将涉及对一小部分事件进行裁决，如果发现不一致，则进行进一步裁决。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37935635/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231108011057&v=2.17.9.post6+86293ac">37935635</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad718>10.1093/eurheartj/ehad718</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37935635</guid><pubDate> Tue, 07 Nov 2023 06:00:00 -0500</pubDate><dc:creator>穆罕默德·沙泽布·汗</dc:creator><dc:creator>穆罕默德·沙里克·乌斯曼</dc:creator><dc:creator>哈里特·GC·范·斯波</dc:creator><dc:creator>斯蒂芬·J·格林</dc:creator><dc:creator>奥马尔·巴卡尔</dc:creator><dc:creator>加里·迈克尔·菲尔克</dc:creator><dc:creator>迪帕克·巴特</dc:creator><dc:creator>詹姆斯·贾努齐</dc:creator><dc:creator>贾维德·巴特勒</dc:creator><dc:date>2023-11-07</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>心血管临床试验中的终点判定</dc:title><dc:identifier>下午:37935635</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad718</dc:identifier></item><item><title> ST 段抬高型心肌梗死期间的室性心律失常以及反复缺血事件期间的心律失常并发症</title><link/>https://pubmed.ncbi.nlm.nih.gov/37935589/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231108011057&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 11 月 3 日：ehad740。doi：10.1093/eurheartj/ehad740。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37935589/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231108011057&v=2.17.9.post6+86293ac">37935589</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad740>10.1093/eurheartj/ehad740</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37935589</guid><pubDate> Tue, 07 Nov 2023 06:00:00 -0500</pubDate><dc:creator>玛丽娜·M·德米多娃</dc:creator><dc:creator>弗雷德里克·霍尔姆奎斯特</dc:creator><dc:creator>大卫·埃尔林格</dc:creator><dc:creator>彼得·G·普拉托诺夫</dc:creator><dc:date>2023-11-07</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>ST 段抬高型心肌梗死期间的室性心律失常以及反复缺血事件期间的心律失常并发症</dc:title><dc:identifier>下午：37935589</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad740</dc:identifier></item><item><title>心律之外：心房颤动、舒张功能障碍和心力衰竭</title><link/>https://pubmed.ncbi.nlm.nih.gov/37935588/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231108011057&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 11 月 3 日：ehad747。doi：10.1093/eurheartj/ehad747。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37935588/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231108011057&v=2.17.9.post6+86293ac">37935588</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad747>10.1093/eurheartj/ehad747</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37935588</guid><pubDate> Tue, 07 Nov 2023 06:00:00 -0500</pubDate><dc:creator>里卡多·M·因西亚迪</dc:creator><dc:creator>斯科特·D·所罗门</dc:creator><dc:date>2023-11-07</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>心律之外：心房颤动、舒张功能障碍和心力衰竭</dc:title><dc:identifier>下午:37935588</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad747</dc:identifier></item><item><title>糖尿病患者经皮冠状动脉介入治疗后的常规压力测试：POST-PCI 试验</title><link/>https://pubmed.ncbi.nlm.nih.gov/37933514/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231108011057&amp;v=2.17.9.post6+86293ac<description>结论：尽管发生不良临床事件的风险较高，但接受高风险 PCI 的糖尿病患者与随访期间单独的标准护理相比，并未从常规监测压力测试中获得更多益处。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 11 月 2 日：ehad722。doi：10.1093/eurheartj/ehad722。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：接受经皮冠状动脉介入治疗（PCI）的高危糖尿病患者的随访监测策略仍不清楚。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：POST-PCI（比较接受经皮冠状动脉介入治疗的高危患者的症状导向与常规压力测试的实用试验）研究是一项随机试验，比较 1 年常规功能测试与单独标准护理的随访策略高风险 PCI 后。根据糖尿病状况进行随机分层。主要结局是全因死亡、心肌梗死或 2 年因不稳定心绞痛住院的复合结局。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在 1706 名随机患者中，与非糖尿病患者（n = 1046 名，61.3%）相比，糖尿病患者（n = 660 名，38.7%）更常见合并症，复杂解剖或手术特征的患病率更高。主要复合事件的风险增加 52% [风险比 (HR) 1.52；95% 置信区间 (CI) 1.02-2.27；P = 0.039]。常规功能治疗策略之间主要复合事件的 2 年发生率相似糖尿病患者（7.1% vs. 7.5%；HR 0.94；95% CI 0.53-1.66；P = .82）和非糖尿病患者（4.6% vs. 5.1%；HR 0.89；95% CI）仅进行检测或标准护理0.51-1.55；P = .68）（糖尿病交互作用项：P = .91）。无论何种情况，常规功能测试组的侵入性冠状动脉造影和 1 年后重复血运重建的发生率均高于标准治疗组。糖尿病状况。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：尽管发生不良临床事件的风险较高，但接受高风险 PCI 的糖尿病患者与随访期间单独的标准护理相比，并未从常规监测压力测试中获得更多益处。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37933514/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231108011057&v=2.17.9.post6+86293ac">37933514</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad722>10.1093/eurheartj/ehad722</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37933514</guid><pubDate> Tue, 07 Nov 2023 06:00:00 -0500</pubDate><dc:creator>金浩润</dc:creator><dc:creator>姜道润</dc:creator><dc:creator>李振浩</dc:creator><dc:creator>崔延佑</dc:creator><dc:creator>安正民</dc:creator><dc:creator>金善玉</dc:creator><dc:creator>尹勇勋</dc:creator><dc:creator>许承浩</dc:creator><dc:creator>李哲贤</dc:creator><dc:creator>金元章</dc:creator><dc:creator>姜世勋</dc:creator><dc:creator>朴哲秀</dc:creator><dc:creator>李奉基</dc:creator><dc:creator>徐正元</dc:creator><dc:creator>崔在雄</dc:creator><dc:creator>金基植</dc:creator><dc:creator>李苏南</dc:creator><dc:creator>朴胜正</dc:creator><dc:creator>朴德宇</dc:creator><dc:date>2023-11-07</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>糖尿病患者经皮冠状动脉介入治疗后的常规压力测试：POST-PCI 试验</dc:title><dc:identifier>下午:37933514</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad722</dc:identifier></item><item><title> Patisiran 有利于治疗 TTR 心脏淀粉样变性</title><link/>https://pubmed.ncbi.nlm.nih.gov/37932423/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231108011057&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Nat Rev Cardiol.2023 年 11 月 6 日。doi：10.1038/s41569-023-00955-2。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37932423/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231108011057&v=2.17.9.post6+86293ac">37932423</a> | DOI： <a href=https://doi.org/10.1038/s41569-023-00955-2>10.1038/s41569-023-00955-2</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37932423</guid><pubDate> Mon, 06 Nov 2023 06:00:00 -0500</pubDate><dc:creator>艾琳·费尔南德斯-鲁伊斯</dc:creator><dc:date>2023-11-06</dc:date><dc:source> 《自然》评论、心脏病学</dc:source><dc:title>Patisiran 有利于治疗 TTR 心脏淀粉样变性</dc:title><dc:identifier>下午:37932423</dc:identifier><dc:identifier> doi:10.1038/s41569-023-00955-2</dc:identifier></item><item><title>药物洗脱可吸收支架治疗腘下动脉疾病优于血管成形术</title><link/>https://pubmed.ncbi.nlm.nih.gov/37932422/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231108011057&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Nat Rev Cardiol。2023 年 11 月 6 日。doi：10.1038/s41569-023-00956-1。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37932422/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231108011057&v=2.17.9.post6+86293ac">37932422</a> | DOI： <a href=https://doi.org/10.1038/s41569-023-00956-1>10.1038/s41569-023-00956-1</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37932422</guid><pubDate> Mon, 06 Nov 2023 06:00:00 -0500</pubDate><dc:creator>卡琳娜·黄</dc:creator><dc:date>2023-11-06</dc:date><dc:source> 《自然》评论、心脏病学</dc:source><dc:title>药物洗脱可吸收支架治疗腘下动脉疾病优于血管成形术</dc:title><dc:identifier>下午:37932422</dc:identifier><dc:identifier> doi:10.1038/s41569-023-00956-1</dc:identifier></item><item><title>需要随机试验来确定慢性肾脏病房颤抗凝剂的最佳剂量</title><link/>https://pubmed.ncbi.nlm.nih.gov/37931022/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231108011057&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 11 月 7 日；148(19):1455-1458. doi: 10.1161/CIRCULATIONAHA.123.066600. Epub 2023 年 11 月 6 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37931022/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231108011057&v=2.17.9.post6+86293ac">37931022</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066600>10.1161/CIRCULATIONAHA.123.066600</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37931022</guid><pubDate> Mon, 06 Nov 2023 06:00:00 -0500</pubDate><dc:creator>肖恩·D·波科尼</dc:creator><dc:creator>克里斯托弗·B·格兰杰</dc:creator><dc:date>2023-11-06</dc:date><dc:source>循环</dc:source><dc:title>需要随机试验来确定慢性肾脏病房颤抗凝剂的最佳剂量</dc:title><dc:identifier>下午：37931022</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.066600</dc:identifier></item><item><title> Li 等人关于文章“严重感染和心血管疾病风险：多队列研究”的信函</title><link/>https://pubmed.ncbi.nlm.nih.gov/37931021/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231108011057&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 11 月 7 日；148(19):1507-1508. doi: 10.1161/CIRCULATIONAHA.123.065349. Epub 2023 年 11 月 6 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37931021/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231108011057&v=2.17.9.post6+86293ac">37931021</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065349>10.1161/CIRCULATIONAHA.123.065349</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37931021</guid><pubDate> Mon, 06 Nov 2023 06:00:00 -0500</pubDate><dc:creator>莎莉</dc:creator><dc:creator>钱杰</dc:creator><dc:creator>李建军</dc:creator><dc:date>2023-11-06</dc:date><dc:source>循环</dc:source><dc:title>Li 等人关于文章“严重感染和心血管疾病风险：多队列研究”的信函</dc:title><dc:identifier>下午：37931021</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.065349</dc:identifier></item><item><title>尼日利亚的心血管疾病：现状、威胁和机遇</title><link/>https://pubmed.ncbi.nlm.nih.gov/37931020/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231108011057&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 11 月 7 日；148(19):1441-1444. doi: 10.1161/CIRCULATIONAHA.123.063671. Epub 2023 年 11 月 6 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37931020/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231108011057&v=2.17.9.post6+86293ac">37931020</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.063671>10.1161/CIRCULATIONAHA.123.063671</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37931020</guid><pubDate> Mon, 06 Nov 2023 06:00:00 -0500</pubDate><dc:creator>奥克丘库·塞缪尔·奥加</dc:creator><dc:creator>奥兰尼克·艾莉森·奥里莫拉德</dc:creator><dc:creator>托米洛拉·奥拉米德·吉纳杜</dc:creator><dc:date>2023-11-06</dc:date><dc:source>循环</dc:source><dc:title>尼日利亚的心血管疾病：现状、威胁和机遇</dc:title><dc:identifier>下午：37931020</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.063671</dc:identifier></item><item><title>宗教/灵性作为医疗处方</title><link/>https://pubmed.ncbi.nlm.nih.gov/37930863/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231108011057&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 11 月 1 日：ehad725。doi：10.1093/eurheartj/ehad725。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37930863/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231108011057&v=2.17.9.post6+86293ac">37930863</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad725>10.1093/eurheartj/ehad725</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37930863</guid><pubDate> Mon, 06 Nov 2023 06:00:00 -0500</pubDate><dc:creator>南丹·阿纳维卡</dc:creator><dc:creator>安库尔·卡拉</dc:creator><dc:date>2023-11-06</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>宗教/灵性作为医疗处方</dc:title><dc:identifier>下午:37930863</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad725</dc:identifier></item><item><title>经股三尖瓣置换术和一年结果：TRISCEND 研究</title><link/>https://pubmed.ncbi.nlm.nih.gov/37930776/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231108011057&amp;v=2.17.9.post6+86293ac<description>结论：在患有≥中度 TR 的老年、高度合并症人群中，接受经股 EVOQUE 经导管电视置换术的患者持续减少 TR，每搏输出量和心输出量显着增加，生存率高，住院率低，临床、功能和质量得到改善一年内的生命结果。由 Edwards Lifesciences 资助，TRISCEND ClinicalTrials.gov 编号，NCT04221490。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 11 月 1 日：ehad667。doi：10.1093/eurheartj/ehad667。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：对于有症状的严重三尖瓣反流 (TR) 患者，经导管三尖瓣 (TV) 干预研究的早期结果表明，与右心逆重塑相关的功能状态和生活质量显着改善。需要-up来确认这些结果的持续改善。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：这项前瞻性、单臂、多中心 TRISCEND 研究招募了 176 名患者，旨在评估经导管 TV 替代治疗对于尽管进行了药物治疗但仍患有≥中度、有症状 TR 的患者的安全性和性能。主要不良事件、TR 等级降低和超声心动图显示的血流动力学结果，并报告一年内的临床、功能和生活质量参数。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：入组患者中 71.0% 为女性，平均年龄 78.7 岁，88.0% ≥ 重度 TR，75.4% 为纽约心脏协会 III-IV 级。97.6% 的三尖瓣反流降至≤轻度（P &lt; .001），其中每搏输出量 (10.5 ± 16.8 mL，P &lt; .001) 和心输出量 (0.6 ± 1.2 L/min，P &lt; .001) 增加。93.3% 的患者达到纽约心脏协会 I 级或 II 级 (P &lt; .001) ），堪萨斯城心肌病问卷评分增加了 25.7 分（P &lt; .001），六分钟步行距离增加了 56.2 m（P &lt; .001）。全因死亡率为 9.1%，10.2% 的患者住院治疗用于心力衰竭。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：在患有≥中度 TR 的老年、高度合并症人群中，接受经股 EVOQUE 经导管电视置换术的患者持续减少 TR，每搏输出量和心输出量显着增加，生存率高，住院率低，临床、功能和质量得到改善一年内的生命结果。由 Edwards Lifesciences 资助，TRISCEND ClinicalTrials.gov 编号，NCT04221490。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37930776/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231108011057&v=2.17.9.post6+86293ac">37930776</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad667>10.1093/eurheartj/ehad667</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37930776</guid><pubDate> Mon, 06 Nov 2023 06:00:00 -0500</pubDate><dc:creator>苏希尔·科达利</dc:creator><dc:creator>丽贝卡·T·哈恩</dc:creator><dc:creator>拉吉·马卡</dc:creator><dc:creator>穆迪·马卡</dc:creator><dc:creator>查尔斯·J·戴维森</dc:creator><dc:creator>乔西·J·普图马纳</dc:creator><dc:creator>菲拉斯·扎尔</dc:creator><dc:creator>斯科特·查德登</dc:creator><dc:creator>尼尔·法姆</dc:creator><dc:creator>杰拉尔丁·翁</dc:creator><dc:creator>普拉迪普·亚达夫</dc:creator><dc:creator>维诺德·图拉尼</dc:creator><dc:creator>玛尼·瓦南</dc:creator><dc:creator>威廉·W·奥尼尔</dc:creator><dc:creator>王迪迪</dc:creator><dc:creator>迪迪埃·切切</dc:creator><dc:creator>尼古拉·杜梦泰</dc:creator><dc:creator>洛朗·邦菲尔斯</dc:creator><dc:creator>洛朗·勒帕吉</dc:creator><dc:creator>罗伯特·史密斯</dc:creator><dc:creator>保罗·格雷伯恩</dc:creator><dc:creator>拉胡尔·夏尔马</dc:creator><dc:creator>克里斯蒂安·海菲尔</dc:creator><dc:creator>瓦西利斯·巴巴利亚罗斯</dc:creator><dc:creator>帕特里克·格里森</dc:creator><dc:creator>萨米·埃尔玛利亚</dc:creator><dc:creator>伊格纳西奥·英格莱西斯·阿苏阿杰</dc:creator><dc:creator>乔纳森·帕塞里</dc:creator><dc:creator>霍华德·赫尔曼</dc:creator><dc:creator>弗兰克·西尔维斯特里</dc:creator><dc:creator>斯科特·林</dc:creator><dc:creator>戴尔·福勒</dc:creator><dc:creator>约翰·G·韦伯</dc:creator><dc:creator>罗伯特·莫斯</dc:creator><dc:creator>托马斯·莫迪恩</dc:creator><dc:creator>斯蒂芬·拉菲特</dc:creator><dc:creator>阿齐姆·拉提布</dc:creator><dc:creator>何浩文</dc:creator><dc:creator>伊森·戈德堡</dc:creator><dc:creator>皮纳克·沙阿</dc:creator><dc:creator>查尔斯·尼曼</dc:creator><dc:creator>何塞普·罗德斯·卡包</dc:creator><dc:creator>伊丽莎白·贝达</dc:creator><dc:creator>尼古拉斯·布鲁格</dc:creator><dc:creator>安娜桑尼诺</dc:creator><dc:creator>迈克尔·J·麦克</dc:creator><dc:creator>马丁·B·莱昂</dc:creator><dc:creator>史蒂芬·温德克</dc:creator><dc:creator>TRISCEND 研究人员</dc:creator><dc:date>2023-11-06</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>经股三尖瓣置换术和一年结果：TRISCEND 研究</dc:title><dc:identifier>下午:37930776</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad667</dc:identifier></item><item><title>感染性心内膜炎抗生素治疗模式的改变：我们准备好了吗？</title><link/> https://pubmed.ncbi.nlm.nih.gov/37930713/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231108011057&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 10 月 31 日：ehad529。doi：10.1093/eurheartj/ehad529。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37930713/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231108011057&v=2.17.9.post6+86293ac">37930713</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad529>10.1093/eurheartj/ehad529</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37930713</guid><pubDate> Mon, 06 Nov 2023 06:00:00 -0500</pubDate><dc:creator>努里亚·费尔南德斯-伊达尔戈</dc:creator><dc:creator>伊格纳西奥·费雷拉-冈萨雷斯</dc:creator><dc:date>2023-11-06</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>感染性心内膜炎抗生素治疗模式的改变：我们准备好了吗？</dc:title><dc:identifier>下午：37930713</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad529</dc:identifier></item><item><title>马凡氏综合症的主动脉夹层：保护生命管</title><link/>https://pubmed.ncbi.nlm.nih.gov/37930286/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231108011057&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 10 月 18 日：S0735-1097(23)07568-X.doi：10.1016/j.jacc.2023.08.054。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37930286/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231108011057&v=2.17.9.post6+86293ac">37930286</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.08.054>10.1016/j.jacc.2023.08.054</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37930286</guid><pubDate> Mon, 06 Nov 2023 06:00:00 -0500</pubDate><dc:creator>艾伦·C·布雷弗曼</dc:creator><dc:date>2023-11-06</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>马凡氏综合症的主动脉夹层：保护生命管</dc:title><dc:identifier>下午:37930286</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.08.054</dc:identifier></item><item><title>马凡氏综合症 B 型夹层的风险：康奈尔大学主动脉瘤登记处</title><link/>https://pubmed.ncbi.nlm.nih.gov/37930285/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231108011057&amp;v=2.17.9.post6+86293ac<description>结论：在我们的当代队列中，B 型夹层比 A 型夹层更常见，并且发生在传统的非手术阈值。B 型夹层与 ARR、独立二尖瓣手术和 II 型夹层的关联表明，该情况下存在更严重的表型延长预期寿命。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol。2023 年 10 月 18 日：S0735-1097(23)07569-1。doi：10.1016/j.jacc.2023.08.055。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：随着预防性主动脉移植术降低了马凡综合征 (MFS) 中 A 型夹层的发生率，现在大多数夹层都是 B 型，其危险因素在很大程度上仍不确定。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：我们在大型单中心 MFS 登记中探讨了 B 型夹层风险的决定因素。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：比较伴有和不伴有 B 型夹层的 MFS 患者的人口统计学和人体测量特征、心血管疾病和手术史。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在 336 名 MFS 患者中，47 名 (14%) 经历过 B 型夹层（A 型夹层为 9%）。B 型夹层患者更有可能接受选择性主动脉根部置换术 (ARR)（79% vs 46%） ; P &lt; 0.001)。在 ARR 后平均 13.3 年，55% 的患者发生 B 型夹层，而 45% 在 ARR 之前或未发生 ARR 时发生 B 型夹层；41 名患者 (87%) 知道自己的 MFS B 型夹层之前的诊断。在进行预夹层成像的患者中，88% 的降主动脉正常或轻度扩张 (&lt;4.0 cm)。在多变量分析中，B 型夹层患者更有可能接受 ARR 和独立二尖瓣手术，进行过 II 型解剖，并且寿命更长。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：在我们的当代队列中，B 型夹层比 A 型夹层更常见，并且发生在传统的非手术阈值。B 型夹层与 ARR、独立二尖瓣手术和 II 型夹层的关联表明，该情况下存在更严重的表型延长预期寿命。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37930285/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231108011057&v=2.17.9.post6+86293ac">37930285</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.08.055>10.1016/j.jacc.2023.08.055</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37930285</guid><pubDate> Mon, 06 Nov 2023 06:00:00 -0500</pubDate><dc:creator>努普尔·纳鲁拉</dc:creator><dc:creator>理查德·B·德弗罗</dc:creator><dc:creator>埃洛伊莎·阿布斯蒂尼</dc:creator><dc:creator>马晓月</dc:creator><dc:creator>乔纳森·温萨夫特</dc:creator><dc:creator>伦纳德·吉拉迪</dc:creator><dc:creator>格蕾丝·P·马隆加</dc:creator><dc:creator>玛丽·J·罗曼</dc:creator><dc:date>2023-11-06</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>马凡氏综合症 B 型夹层的风险：康奈尔大学主动脉瘤登记处</dc:title><dc:identifier>下午:37930285</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.08.055</dc:identifier></item><item><title>介入心脏病学热点：左主干病变、冠状动脉严重钙化狭窄、生理学引导下的经皮冠状动脉介入治疗</title><link/>https://pubmed.ncbi.nlm.nih.gov/37930000/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231108011057&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 11 月 1 日；44(41):4295-4299.doi: 10.1093/eurheartj/ehad721。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37930000/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231108011057&v=2.17.9.post6+86293ac">37930000</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad721>10.1093/eurheartj/ehad721</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37930000</guid><pubDate> Mon, 06 Nov 2023 06:00:00 -0500</pubDate><dc:creator>菲利波·克雷亚</dc:creator><dc:date>2023-11-06</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>介入心脏病学热点：左主干病变、冠状动脉严重钙化狭窄、生理学引导下的经皮冠状动脉介入治疗</dc:title><dc:identifier>下午：37930000</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad721</dc:identifier></item><item><title>儿科心肺复苏期间呼气末二氧化碳、心肺复苏质量和生存之间的关联</title><link/>https://pubmed.ncbi.nlm.nih.gov/37929615/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231108011057&amp;v=2.17.9.post6+86293ac<description>背景：在成人心肺骤停的实验室和临床研究的支持下，复苏指南建议监测呼气末二氧化碳（ETCO2）作为心肺复苏质量的指标，但指出“尚未建立指导儿童治疗的具体值”。方法：这项前瞻性观察队列研究是 NHLBI 资助的一项针对 ICU-RESUSitation 试验中儿童的辅助研究 (NCT02837497)。住院儿童（≤18 岁且≥37 周... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 11 月 6 日。doi：10.1161/CIRCULATIONAHA.123.066659。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>背景：</b>在成人心肺骤停的实验室和临床研究的支持下，复苏指南建议监测呼气末二氧化碳（ETCO2）作为心肺复苏质量的指标，但指出“尚未建立指导儿童治疗的具体值”。<b>方法：</b>这项前瞻性观察队列研究是一项 NHLBI 资助的针对<i>ICU-RESUS</i>引文试验 (NCT02837497) 儿童的辅助研究。接受过任何胸外按压的住院儿童（≤18 岁且孕后≥37 周）包括心肺骤停持续时间、在 CPR 开始时有气管插管或气管切开插管、以及可评估的逮捕期间 ETCO2 数据。主要暴露是 CPR 前 10 分钟内事件水平的平均 ETCO2（分为 ≥20 mmHg）与基于成人文献的 &lt;20 mmHg 相比）。主要结局是出院时的生存率。次要结局是自主循环 (ROSC) 的持续恢复、神经系统结果良好的出院时的生存率以及幸存者中的新发病率。泊松回归关联测量ETCO2 与结果之间的关系以及 ETCO2 与其他 CPR 特征之间的关联：1) 有创测量的收缩压和舒张压，2) CPR 质量和胸外按压力学指标（即 CPR 开始时间、胸外按压频率、深度和<b>结果：</b>在纳入的 234 名患者中，133 名 (57%) 的事件水平平均 ETCO2 ≥20 mmHg。在控制<i>先验</i>协变量后，平均 ETCO2 ≥20 mmHg 与较高的出院生存率相关（86/ 133 (65%) 对比 48/101 (48%)；aRR 1.33，CI95 1.04 - 1.69，p=0.023) 和 ROSC (95/133 (71%) 59/101 (58%)；aRR 1.22，CI95 1.00 - 1.49，p=0.046）与较低值相比。ETCO2 ≥20 mmHg 与生存者的良好神经系统结果或新发病率无关。平均 ETCO2 ≥20 mmHg 与 CPR 期间较高的收缩压和舒张压、较低的 CPR 通气量相关与较低值相比，CPR 前逮捕持续时间较短。ETCO2 组之间的胸外按压率、深度和分数没有差异。<b>结论：</b>在这项针对院内心肺骤停儿童的多中心研究中，ETCO2 ≥20 mmHg 与具有更好的结果和更高的逮捕内血压，但胸外按压质量指标却没有。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37929615/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231108011057&v=2.17.9.post6+86293ac">37929615</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066659>10.1161/CIRCULATIONAHA.123.066659</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37929615</guid><pubDate> Mon, 06 Nov 2023 06:00:00 -0500</pubDate><dc:creator>瑞安·W·摩根</dc:creator><dc:creator>罗恩·W·里德</dc:creator><dc:creator>迪特·本德</dc:creator><dc:creator>凯利玛丽·K·库珀</dc:creator><dc:creator>斯图尔特·H·弗里斯</dc:creator><dc:creator>凯瑟琳·格雷厄姆</dc:creator><dc:creator>凯瑟琳·L·梅尔特</dc:creator><dc:creator>彼得·莫拉尼</dc:creator><dc:creator>罗伯特·默里</dc:creator><dc:creator>维奈·M·纳德卡尼</dc:creator><dc:creator>C纳塔拉杰</dc:creator><dc:creator>切拉·帕尔默</dc:creator><dc:creator>尼拉杰·斯里瓦斯塔瓦</dc:creator><dc:creator>布拉德利·蒂尔福德</dc:creator><dc:creator>希瑟·沃尔夫</dc:creator><dc:creator>安德鲁·耶茨</dc:creator><dc:creator>罗伯特·伯格</dc:creator><dc:creator>罗伯特·萨顿</dc:creator><dc:date>2023-11-06</dc:date><dc:source>循环</dc:source><dc:title>儿科心肺复苏期间呼气末二氧化碳、心肺复苏质量和生存之间的关联</dc:title><dc:identifier>下午:37929615</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.066659</dc:identifier></item><item><title>炎症和胆固醇作为 13970 名当代他汀类药物不耐受高危患者心血管事件的预测因子</title><link/>https://pubmed.ncbi.nlm.nih.gov/37929602/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231108011057&amp;v=2.17.9.post6+86293ac<description> Background: Among patients treated with statin therapy to guideline-recommended cholesterol levels, residual inflammatory risk assessed by high-sensitivity C-reactive protein (hsCRP) is at least as strong a predictor of future cardiovascular events as is residual risk assessed by low-density lipoprotein cholesterol (LDLC). Whether these relationships are present among statin-intolerant patients with higher LDLC levels is uncertain but has implications for the choice of preventive therapies,... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Nov 6. doi: 10.1161/CIRCULATIONAHA.123.066213. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> <b>Background:</b> Among patients treated with statin therapy to guideline-recommended cholesterol levels, residual inflammatory risk assessed by high-sensitivity C-reactive protein (hsCRP) is at least as strong a predictor of future cardiovascular events as is residual risk assessed by low-density lipoprotein cholesterol (LDLC). Whether these relationships are present among statin-intolerant patients with higher LDLC levels is uncertain but has implications for the choice of preventive therapies, including bempedoic acid, an agent that reduces both LDLC and hsCRP. <b>Methods:</b> The multinational CLEAR-Outcomes trial (Cholesterol Lowering via Bempedoic Acid, an ACL-Inhibiting Regimen Outcomes Trial) randomly allocated 13970 statin-intolerant patients to 180 mg of oral bempedoic acid daily or matching placebo and followed them for a 4-component composite of incident myocardial infarction, stroke, coronary revascularization, or cardiovascular death, and for all-cause mortality. Quartiles of increasing baseline hsCRP and LDLC were assessed as predictors of future adverse events after adjustment for traditional risk factors and randomized treatment assignment. <b>Results:</b> Compared with placebo, bempedoic acid reduced median hsCRP by 21.6% and mean LDLC levels by 21.1% at 6 months. Baseline hsCRP was significantly associated with the primary composite end point of major cardiovascular events (highest versus lowest hsCRP quartile; hazard ratio [HR], 1.43 [95% CI, 1.24-1.65]), cardiovascular mortality (HR, 2.00 [95% CI, 1.53-2.61]), and all-cause mortality (HR, 2.21 [95% CI, 1.79-2.73]). By contrast, the relationship of baseline LDLC quartile (highest versus lowest) to future events was smaller in magnitude for the primary composite cardiovascular end point (HR, 1.19 [95% CI, 1.04-1.37]) and neutral for cardiovascular mortality (HR, 0.90 [95% CI, 0.70-1.17]) and all-cause mortality (HR, 0.95 [95% CI, 0.78-1.16]). Risks were high for those with elevated hsCRP irrespective of LDLC level. Bempedoic acid demonstrated similar efficacy in reducing cardiovascular events across all levels of hsCRP and LDLC. <b>Conclusions:</b> Among contemporary statin-intolerant patients, inflammation assessed by hsCRP predicted risk for future cardiovascular events and death more strongly than hyperlipidemia assessed by LDLC. Compared with placebo, bempedoic acid had similar efficacy for reducing cardiovascular risk across hsCRP and LDLC strata.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37929602/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231108011057&v=2.17.9.post6+86293ac">37929602</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066213>10.1161/CIRCULATIONAHA.123.066213</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37929602</guid><pubDate> Mon, 06 Nov 2023 06:00:00 -0500</pubDate><dc:creator> Paul M Ridker</dc:creator><dc:creator> Lei Lei</dc:creator><dc:creator> Michael J Louie</dc:creator><dc:creator> Tariq Haddad</dc:creator><dc:creator> Stephen J Nicholls</dc:creator><dc:creator> A Michael Lincoff</dc:creator><dc:creator> Peter Libby</dc:creator><dc:creator> Steven E Nissen</dc:creator><dc:date> 2023-11-06</dc:date><dc:source> Circulation</dc:source><dc:title> Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13970 Contemporary High-Risk Patients With Statin Intolerance</dc:title><dc:identifier> pmid:37929602</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.066213</dc:identifier></item><item><title> A Diagnostic CopyCat: Culture-Negative Infective Endocarditis of a Bioprosthetic Valve Presenting as ANCA Vasculitis</title><link/> https://pubmed.ncbi.nlm.nih.gov/37929592/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231108011057&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Nov 6. doi: 10.1161/CIRCULATIONAHA.123.067136. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37929592/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231108011057&v=2.17.9.post6+86293ac">37929592</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067136>10.1161/CIRCULATIONAHA.123.067136</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37929592</guid><pubDate> Mon, 06 Nov 2023 06:00:00 -0500</pubDate><dc:creator> David E Hamilton</dc:creator><dc:creator> Sandro K Cinti</dc:creator><dc:creator> Cathryn J Lapedis</dc:creator><dc:creator> Kim A Eagle</dc:creator><dc:date> 2023-11-06</dc:date><dc:source> Circulation</dc:source><dc:title> A Diagnostic CopyCat: Culture-Negative Infective Endocarditis of a Bioprosthetic Valve Presenting as ANCA Vasculitis</dc:title><dc:identifier> pmid:37929592</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.067136</dc:identifier></item><item><title> Meta-analysis of Penetrance and Systematic Review on Transition to Disease in Genetic Hypertrophic Cardiomyopathy</title><link/> https://pubmed.ncbi.nlm.nih.gov/37929589/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231108011057&amp;v=2.17.9.post6+86293ac<description> Background: Hypertrophic cardiomyopathy (HCM) is characterized by unexplained left ventricular hypertrophy (LVH) and is classically caused by pathogenic or likely pathogenic variants (P/LP) in genes encoding sarcomere proteins. Not all subclinical variant carriers will manifest clinically overt disease, as penetrance (proportion of G+ who develop disease) is variable, age-dependent, and not reliably predicted. Methods: A systematic search of the literature was performed. We employed random... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Nov 6. doi: 10.1161/CIRCULATIONAHA.123.065987. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> <b>Background:</b> Hypertrophic cardiomyopathy (HCM) is characterized by unexplained left ventricular hypertrophy (LVH) and is classically caused by pathogenic or likely pathogenic variants (P/LP) in genes encoding sarcomere proteins. Not all subclinical variant carriers will manifest clinically overt disease, as penetrance (proportion of G+ who develop disease) is variable, age-dependent, and not reliably predicted. <b>Methods:</b> A systematic search of the literature was performed. We employed random effects generalized linear mixed model meta-analyses to contrast the cross-sectional prevalence and penetrance of sarcomere genes in two different contexts: clinically-based studies on patients and families with HCM versus population/community-based studies. Longitudinal family/clinical studies were additionally analyzed to investigate the rate of phenotypic conversion from subclinical to overt HCM during follow-up. <b>Results:</b> 455 full text manuscripts were assessed. In family/clinical studies, the prevalence of sarcomere variants in patients diagnosed with HCM was 34%. The penetrance across all genes in non-proband relatives carrying P/LP variants identified during cascade screening was 57% (95% confidence interval [CI] [52,63]) and the mean age of HCM diagnosis was 38 years (95% CI [36, 40]). Penetrance varied from ~32% for myosin light chain ( <i>MYL3</i> ) to ~55% for myosin binding protein C ( <i>MYBPC3</i> ), ~60% troponin T ( <i>TNNT2</i> ) and troponin I ( <i>TNNI3</i> ), and ~65% for myosin heavy chain ( <i>MYH7</i> ). Population-based genetic studies demonstrate that P/LP sarcomere variants are present in the background population, but at a low prevalence of &lt;1%. The penetrance of HCM in incidentally identified P/LP variant carriers was also substantially lower; approximatively 11%, ranging from 0% in Atherosclerosis Risk in Communities to 18% in UK Biobank. In longitudinal family studies, the pooled phenotypic conversion across all genes was 15% over an average of ~8 years of follow up, starting from a mean age of ~16 years. However, short-term gene-specific phenotypic conversion varied between ~12% for <i>MYBPC3</i> to ~23% for <i>MYH7</i> . <b>Conclusions:</b> The penetrance of P/LP variants is highly variable and influenced by currently undefined and context-dependent genetic and environmental factors. Additional longitudinal studies are needed to improve understanding of true lifetime penetrance in families and in the community, and to identify drivers of the transition from subclinical to overt HCM.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37929589/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231108011057&v=2.17.9.post6+86293ac">37929589</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065987>10.1161/CIRCULATIONAHA.123.065987</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37929589</guid><pubDate> Mon, 06 Nov 2023 06:00:00 -0500</pubDate><dc:creator> Constantin-Cristian Topriceanu</dc:creator><dc:creator> Alexandre C Pereira</dc:creator><dc:creator> James C Moon</dc:creator><dc:creator> Gabriella Captur</dc:creator><dc:creator> Carolyn Y Ho</dc:creator><dc:date> 2023-11-06</dc:date><dc:source> Circulation</dc:source><dc:title> Meta-analysis of Penetrance and Systematic Review on Transition to Disease in Genetic Hypertrophic Cardiomyopathy</dc:title><dc:identifier> pmid:37929589</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.065987</dc:identifier></item></channel></rss>